ClinicalTrials.gg
RecruitingNCT07572812Updated Nov 4, 2026

A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

A Phase 1 interventional study of UX-GIP001 in Epilepsy, sponsored by Shanghai UniXell Biotechnology Co., Ltd. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Shanghai UniXell Biotechnology Co., Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Epilepsy with a site in China — 35 open to participants now, 41 under way, 5 of them phase 3. Epilepsy · China.

Planned enrollment
57th of 64
12 · median 141
Started
2026
with 8 others
Phase 1
10 of 101
4 open now
Primary completion
2029-07
later than 37 of 40 live
Registered
96th of 101
by date

Among the 101 studies in Epilepsy with a site in China, this one is the 57th largest by planned enrollment of the 64 interventional ones that give a count, is one of 9 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 37 of the 40 other live ones, and was the 96th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

35 of the 101 studies in Epilepsy with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Epilepsy with a site in China, or all of them as a file.
02

Study summary

This is a phase I study (Protocol: UX-GIP001-102) investigating UX-GIP001 Injection, a novel cell therapy product consisting of human GABAergic interneuron progenitor cells (GIP), for treating adult patients with drug-resistant unilateral medial temporal lobe epilepsy (MTLE). The primary objective is to assess the safety, tolerability, and preliminary efficacy of UX-GIP001. This is an open-label, single-arm study. All enrolled participants will receive the active investigational cell therapy. Seizure frequency and safety parameters will be evaluated by comparing post-transplant outcomes to pre-transplant baselines.

Read the detailed description

Participants will receive UX-GIP001 via stereotactic neurosurgery, preceded by and followed with immunosuppressive therapy. The study includes a baseline period for eligibility confirmation and a 24-month follow-up phase involving regular safety assessments, neuroimaging , seizure diary logging, and evaluations of quality of life, cognition, and mood. This pioneering regenerative approach seeks to provide a new treatment strategy for drug-resistant MTLE by addressing the underlying pathophysiology.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • MTLE
  • Cell therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years (inclusive), male or female;
  • Diagnosis of focal epilepsy according to the International League Against Epilepsy (ILAE) 2025 epilepsy classification, with disease duration ≥2 years;
  • Clinical presentation consistent with unilateral mesial temporal lobe epilepsy (MTLE);
  • Meeting the diagnostic criteria for drug-resistant epilepsy;
  • Average focal seizure frequency ≥4 per 28 days within the 3 months prior to screening;
  • On a stable dose of anti-seizure medications for ≥1 month prior to enrollment;
  • Patient has adequate organ function as follows: ≥2.0×10⁹/L; white blood cell count ≥4.0×10⁹/L; count ≥100×10⁹/L; and ALT ≤2.5× (ULN); total ≤1.5× ULN; serum creatinine ≤1.5× ULN; estimated (eGFR) ≥60 mL/min/1.73 m² (calculated using the CKD-EPI formula);
  • Women of must have a negative serum pregnancy test during the screening period. All participants and their partners agree to have no plans for pregnancy, sperm donation, or egg donation from the time of signing the form until 2 years after cell transplantation treatment, and voluntarily adopt measures deemed effective by the investigator;
  • Patient has good compliance, with a patient diary completion rate ≥80% prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Epilepsy caused by other/or progressive neurological diseases , or patients - experiencing only focal aware seizures without observable manifestations.
  • History of epilepsy surgery.
  • History of status epilepticus within 12 months prior to screening.
  • Presence of long-term implants in the skull or intracranial space.
  • Severe systemic disease or dysfunction.
  • Primary or secondary immunodeficiency.
  • History of clear suicidal intent, plan, or behavior within one year prior to screening.
  • Severe psychiatric disorders.
  • History of within the past 5 years, except for cervical carcinoma in situ, basal cell or squamous cell skin cancer cured for >5 years.
  • Pregnant or breastfeeding women.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    UX-GIP001

    Two dose levels will be planned. Each patient only receives one corresponding dose of UX-GIP001.

    Drug: UX-GIP001

Interventions

  • DrugUX-GIP001

    Allogeneic human GABAergic interneuron precursors (UX-GIP001) are delivered into the temporal lobe region of the brain.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Adverse Events (AEs)/Serious Adverse Events (SAEs)

    Time frame: From baseline to 6 Months post-treatment

Secondary outcomes

  1. Change from baseline in total and subtype seizure frequency

    Time frame: From baseline to 2 years post-treatment

  2. Responder rates (≥50% and ≥75% reduction) in total and subtype seizure frequency

    Time frame: From baseline to 2 years post-treatment

  3. Seizure free rate

    Time frame: From baseline to 2 years post-treatment

  4. Incidence and severity of AEs/SAEs related to surgery, transplanted cells, and/or immunosuppressive therapy

    Time frame: From baseline to 2 years post-treatment

  5. Incidence and severity of all AEs/SAEs

    Time frame: From baseline to 2 years post-treatment

07

Study locations

2 of 3 sites recruiting
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing Municipality 100070, China
    Recruiting
    • Xiaoqiu Shao · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450000, China
    Not yet recruiting
    • Qun Wang · Contact
  • West China School of Medicine and West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
    Recruiting
    • Dong Zhou, Doctor · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2029, 33 months after the start.

Of 34 industry-sponsored phase 1 interventional studies under Epilepsy, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's planned 33 months is above that.

Counting every sponsor, half of 55 studies reached it within 8 months; a quarter within 3 and three quarters within 22.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
May 7, 2026
StartActual
Sep 5, 2026was Aug 2026
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
3 sites changed recruiting status (2 now recruiting, 1 now not yet recruiting)
Show 3 sites
  • Beijing Tiantan Hospital, Capital Medical University · Beijing, Chinano status→Recruiting
  • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Not yet recruiting
  • West China School of Medicine and West China Hospital, Sichuan University · Chengdu, Chinano status→Recruiting
Nov 4, 2026
Start date
Aug 20, 2026→Sep 5, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now recruiting, 1 now not yet recruiting)
    Show 3 sites
    • Beijing Tiantan Hospital, Capital Medical University · Beijing, Chinano status→Recruiting
    • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Not yet recruiting
    • West China School of Medicine and West China Hospital, Sichuan University · Chengdu, Chinano status→Recruiting
    Start date Aug 20, 2026→Sep 5, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07572812
Lead sponsor
Shanghai UniXell Biotechnology Co., Ltd
Responsible party
Sponsor
First posted
May 7, 2026
Start date
Sep 5, 2026
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Xianwei Zhi
Contact
xianweizhi@unixell.com
+86-21-60197620
Dong Zhou, Doctor
principal investigator · West China Hospital
Xiaoqiu Shao, Doctor
principal investigator · Beijing Tiantan Hospital
Qun Wang, Doctor
principal investigator · The First Affiliated Hospital of Zhengzhou University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion